My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 412

    1.

    Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

    Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.

    Diabetes Care. 2000 Nov;23(11):1660-5.PMID: 11092289 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.

    Ristic S, Collober-Maugeais C, Pecher E, Cressier F.

    Diabet Med. 2006 Jul;23(7):757-62.PMID: 16842480 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

    Hirschberg Y, Karara AH, Pietri AO, McLeod JF.

    Diabetes Care. 2000 Mar;23(3):349-53.PMID: 10868864 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.

    Horton ES, Foley JE, Shen SG, Baron MA.

    Curr Med Res Opin. 2004 Jun;20(6):883-9.PMID: 15200747 [PubMed - indexed for MEDLINE]Related articles

    5.

    Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

    Hanefeld M, Bouter KP, Dickinson S, Guitard C.

    Diabetes Care. 2000 Feb;23(2):202-7.PMID: 10868832 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

    Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.

    Diabetes Care. 2003 Jun;26(6):1685-90.PMID: 12766094 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.

    Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA.

    Diabetes Care. 2005 Sep;28(9):2093-9.PMID: 16123472 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.

    Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C.

    Diabetes Obes Metab. 2002 May;4(3):177-86.PMID: 12047396 [PubMed - indexed for MEDLINE]Related articles

    9.

    Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

    Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE.

    Diabetes Care. 2001 Jun;24(6):983-8.PMID: 11375357 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.

    Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pecher E.

    Diabetes Obes Metab. 2007 Jul;9(4):506-11.PMID: 17587393 [PubMed - indexed for MEDLINE]Related articles

    11.

    Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

    Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

    J Clin Pharm Ther. 2009 Feb;34(1):13-23.PMID: 19125899 [PubMed - indexed for MEDLINE]Related articles

    12.

    Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.

    Weaver JU, Robertson D, Atkin SL.

    Diabetes Obes Metab. 2004 Sep;6(5):344-52.PMID: 15287927 [PubMed - indexed for MEDLINE]Related articles

    13.

    Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

    Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group.

    Diabetes Care. 2003 Jul;26(7):2063-8. Erratum in: Diabetes Care. 2003 Sep;26(9):2708. PMID: 12832314 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).

    Gribble FM, Manley SE, Levy JC.

    Diabetes Care. 2001 Jul;24(7):1221-5.PMID: 11423506 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    16.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    17.

    The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

    Diabetes Care. 1998 May;21(5):701-5.PMID: 9589227 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

    Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H.

    Diabetes Care. 1999 Jan;22(1):119-24.PMID: 10333912 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.

    Goldstein BJ, Pans M, Rubin CJ.

    Clin Ther. 2003 Mar;25(3):890-903.PMID: 12852706 [PubMed - indexed for MEDLINE]Related articles

    20.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity